The new fluoroquinolones: A critical review

Canadian Journal of Infectious Diseases

Volumn 10, Issue 3, 1999, Pages 207-238

  Zhanel, George G ^a,b,c   Walkty, Andrew ^a   Vercaigne, Lavern ^a   Karlowsky, James A ^a,b   Embil, John ^a,b   Gin, Alfred S ^a   Hoban, Daryl J ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Fluoroquinolones; Grepafloxacin; Levofloxacin; Moxifloxacin; Trovafloxacin

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIHISTAMINIC AGENT; ANTIMALARIAL AGENT; ANTIPROTOZOAL AGENT; ASTEMIZOLE; BRETYLIUM; CHLOROQUINE; CIPROFLOXACIN; CLINAFLOXACIN; COTRIMOXAZOLE; DISOPYRAMIDE; ERYTHROMYCIN; GATIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; PHENYTOIN; PROCAINAMIDE; PROKINETIC AGENT; PSYCHOTROPIC AGENT; QUINIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SOTALOL; SPARFLOXACIN; TERFENADINE; THEOPHYLLINE; TROVAFLOXACIN; UNINDEXED DRUG; WARFARIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CARDIOTOXICITY; DRUG COST; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LIVER TOXICITY; PHOTOTOXICITY; RESPIRATORY TRACT INFECTION; REVIEW; URINARY TRACT INFECTION; VERTIGO;

EID: 0032802806     PISSN: 11802332     EISSN: None     Source Type: Journal    
DOI: 10.1155/1999/378394     Document Type: Review

References (257)

1. Andriole VT. The future of the quinolones. Drugs 1993;45 (Suppl 3):1-7.
2. Buchbinder M, Webb JC, Anderson L, McCabe WR. Laboratory studies and clinical pharmacology of nalidixic acid (WIN 18,320). Antimicrob Agents Chemother 1962:308-17.
3. Gillis MC, ed. Compendium of Pharmaceuticals and Specialties. Ottawa: Canadian Pharmacists Association, 1998:318-21, 1083-4.
4. Ronald AR, Turck M, Petersdorf RG. A critical evaluation of nalidixic acid in urinary-tract infections. N Engl J Med 1966;275:1081-8.
5. Wainwright NJ, Collins P, Ferguson J. Photosensitivity associated with antibacterial agents. Drug Saf 1993;9:437-40.
6. Davis R, Markham A, Balfour JA. Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs 1996;51:1019-74.
7. Neu HC. Chemical evolution of the fluoroquinolone antimicrobial agents. Am J Med 1989;87(Suppl 6C):2S-9S.
8. Domagala JM. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother 1994;33:685-706.
9. Goa KL, Bryson HM, Markham A. Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections. Drugs 1997;53:700-25.
10. Cohen MA, Huband MD, Gage JW, Yoder SL, Roland GE, Gracheck SJ. In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin. J Antimicrob Chemother 1997;40:205-11.
11. Hosaka M, Kinoshita S, Toyama A, Otsuki M, Nishino T. Antibacterial properties of AM-1155, a new 8-methoxy quinolone. J Antimicrob Chemother 1995;36:293-301.
12. Wagstaff AJ, Balfour JA. Grepafloxacin. Drugs 1997;53:817-24.
13. Davis R, Bryson HM. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994;47:677-700.
14. Dalhoff A, Petersen U, Endermann R. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotheraphy 1996;42:410-25.
15. Brighty KE, Gootz TD. The chemistry and biological profile of trovafloxacin. J Antimicrob Chemother 1997;39(Suppl B):1-14.
16. Bryskier A, Chantot JF. Classification and structure-activity relationships of fluoroquinolones. Drugs 1995;49(Suppl 2):16-28.
17. Mizuki Y, Fujiwara I, Yamaguchi T. Pharmacokinetic interactions related to the chemical structures of fluoroquinolones. J Antimicrob Chemother 1996;37(Suppl A):41-55.
18. Deppermann KM, Lode H. Fluoroquinolones: interaction profile during enterai absorption. Drugs 1993;45(Suppl 3):65-72.
19. Tanaka M, Kurata T, Fujisawa C, et al. Mechanistic study of inhibition of levofloxacin absorption by aluminum hydroxide. Antimicrob Agents Chemother 1993;37:2173-8.
20. Bryan LE, Bedard J, Wong S, Chamberland S. Quinolone antimicrobial agents: mechanism of action and resistance development. Clin Invest Med 1989;12:14-9.
21. Hooper DC. Quinolone mode of action. Drugs 1995;49(Suppl 2):10-5.
22. Wolfson JS, Hooper DC. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev 1989;2:378-424.
23. Hoshino K, Kitamura A, Morrissey I, Sato K, Kato JI, Ikeda H. Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition. Antimicrob Agents Chemother 1994;38:2623-7.
24. Peng H, Marians KJ. Escherichia coli topoisomerase IV. J Biol Chem 1993;268:24481-90.
25. Kato JI, Nishimura Y, Imamura R, Niki H, Hiraga S, Suzuki H. New topoisomerase essential for chromosome segregation in E coli. Cell 1990;63:393-404.
26. Gootz TD, Zaniewski R, Haskell S, et al. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrob Agents Chemother 1996;40:2691-7.
27. Ferrero L, Cameron B, Crouzet J. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother 1995;39:1554-8.
28. Janoir C, Zeller V, Kitzis MD, Moreau NJ, Gutmann L. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob Agents Chemother 1996;40:2760-4.
29. Pan XS, Fisher LM. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob Agents Chemother 1997;41:471-4.
30. Heisig P. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother 1996;40:879-85.
31. Yoshida H, Bogaki M, Nakamura M, Yamanaka LM, Nakamura S. Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob Agents Chemother 1991;35:1647-50.
32. Piddock LJV. Mechanisms of resistance to fluoroquinolones: state-of-the-art 1992-1994. Drugs 1995;49(Suppl 2):29-35.
33. Hooper DC, Wolfson JS, Souza KS, Tung C, McHugh GL, Swartz MN. Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli. Antimicrob Agents Chemother 1986;29:639-44.
34. Nakanishi N, Yoshida S, Wakebe H, Inoue M, Yamaguchi T, Mitsuhashi S. Mechanisms of clinical resistance to fluoroquinolones in Staphylococcus aureus. Antimicrob Agents Chemother 1991;35:2562-7.
35. Kaatz GW, Seo SM, Ruble CA. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1993;37:1086-94.
36. Ng EYW, Trucksis M, Hooper DC. Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome. Antimicrob Agents Chemother 1994;38:1345-55.
37. Li XZ, Livermore DM, Nikaido H. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol and norfloxacin. Antimicrob Agents Chemother 1994;38:1732-41.
38. Deguchi T, Yasuda M, Nakano M, et al. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in gyrA and parC. Chemotherapy 1997;43:239-44.
39. Barry AL, Fuchs PC, Brown SD. In vitro activities of five fluoroquinolone compounds against strains of Streptococcus pneumoniae with resistance to other antimicrobial agents. Antimicrob Agents Chemother 1996;40:2431-3.
40. Fukuda H, Hiramatsu K. Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother 1999;43:410-2.
41. Jorgensen JH, Weigel LM, Ferraro MJ, Swenson JM, Tenover FC. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC and parE loci. Antimicrob Agents Chemother 1999;43:329-34.
42. National Committee for Clinical Laboratory Standards (NCCLS) Performance Standards For Antimicrobial Susceptibility Testing: 8th Informational Supplement. Villanova: NCCLS, 1998.
43. Brueggemann AB, Kugler KC, Doern GV. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother 1997;41:1594-7.
44. Rolston KVI, Ho DH, Leblanc B, Streeter H, Dvorak T. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer. J Antimicrob Chemother 1997;39(Suppl B):15-22.
45. Felmingham D, Robbins MJ, Ingley K, et al. In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates. J Antimicrob Chemother 1997;39(Suppl B):43-9.
46. Marco F, Jones RN, Hoban DJ, Pignatari AC, Yamane N, Frei R. In-vitro activity of OPC-17116 against more than 6000 consecutive clinical isolates: a multicentre international study. J Antimicrob Chemother 1994;33:647-54.
47. Fuchs PC, Barry AL, Brown SD, Sewell DL. In vitro activity and selection of disk content for disk diffusion susceptibility tests with trovafloxacin. Eur J Clin Microbiol Infect Dis 1996;15:678-82.
48. Biedenbach DJ, Jones RN. The comparative antimicrobial activity of levofloxacin tested against 350 clinical isolates of streptococci. Diagn Microbiol Infect Dis 1996;25:47-51.
49. Thomson KS, Chartrand SA, Sanders CC, Block SL. Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae. Antimicrob Agents Chemother 1997;41:478-80.
50. Flamm RK, Vojtko C, Chu DTW, et al. In vitro evaluation of ABT-719, a novel DNA gyrase inhibitor. Antimicrob Agents Chemother 1995;39:964-70.
51. Schouten MA, Hoogkamp-Korstanje JAA. Comparative in-vitro activities of quinupristin-dalfopristin against Gram-positive bloodstream isolates. J Antimicrob Chemother 1997;40:213-9.
52. Cohen MA, Huband MD, Mailloux GB, Yoder SL, Roland GE, Heifetz CL. In vitro antibacterial activities of the fluoroquinolones PD 117596, PD124816, and PD 127391. Diagn Microbiol Infect Dis 1991;14:245-58.
53. Shonekan D, Handwerger S, Mildvan D. Comparative in-vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against Gram-positive bacteria. J Antimicrob Chemother 1997;39:405-9.
54. Bauernfeind A. Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990. J Antimicrob Chemother 1993;31:505-22.
55. Michelet C, Avril JL, Arvieux C, Jacquelinet C, Vu N, Cartier F. Comparative activities of new fluoroquinolones, alone or in combination with amoxicillin, trimethoprim-sulfamethoxazole, or rifampin, against intracellular Listeria monocytogenes. Antimicrob Agents Chemother 1997;41:60-5.
56. Hosaka M, Yasue T, Fukuda H, Tomizawa H, Aoyama H, Hirai K. In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother 1992;36:2108-17.
57. Wise R, Brenwald NP, Andrews JM, Boswell F. The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones. J Antimicrob Chemother 1997;39:447-52.
58. Wakabayashi E, Mitsuhashi S. In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother 1994;38:594-601.
59. Sader HS, Erwin ME, Jones RN. In vitro activity of OPC-17116 compared to other broad-spectrum fluoroquinolones. Eur J Clin Microbiol Infect Dis 1992;11:372-81.
60. Wiedemann B, Heisig P. Antibacterial activity of grepafloxacin. J Antimicrob Chemother 1997;40(Suppl A):19-25.
61. Wise R, Andrews JM. The activity of grepafloxacin against respiratory pathogens in the UK. J Antimicrob Chemother 1997;40(Suppl A):27-30.
62. Pankuch GA, Jacobs MR, Appelbaum PC. Activity of CP 99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci. J Antimicrob Chemother 1995;35:230-2. (Lett)
63. Cormican MG, Jones RN. Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone. Antimicrob Agents Chemother 1997;41:204-11.
64. Biedenbach DJ, Jones RN. In vitro evaluation of DV-7751a, a new fluoroquinolone with an enhanced spectrum of activity against Gram-positive aerobic organisms and anaerobes. Antimicrob Agents Chemother 1995;39:1636-43.
65. Eliopoulos GM, Wennersten CB, Moellering RC Jr. Comparative in vitro activity of levofloxacin and ofloxacin against Gram-positive bacteria. Diagn Microbiol Infect Dis 1996;25:35-41.
66. Johnson AP, Speller DCE, Warner M, Domingue G. In-vitro activity of levofloxacin (1-ofloxacin) and ciprofloxacin against clinical isolates of Streptococcus pneumoniae obtained in England and Wales. J Antimicrob Chemother 1996;38:907-8. (Lett)
67. Takahashi Y, Masuda N, Otsuki M, Miki M, Nishino T. In vitro activity of HSR-903, a new quinolone. Antimicrob Agents Chemother 1997;41:1326-30.
68. Fass RJ. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone. Antimicrob Agents Chemother 1997;41:1818-24.
69. Woodcock JM, Andrews JM, Boswell FJ, Brenwald NP, Wise R. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother 1997;41:101-6.
70. Felmingham D, Robbins MJ, Leakey A, et al. In vitro activity of BAY 12-8039. Eighth European Congress of Clinical Microbiology and Infectious Diseases. May 25-28, 1997. Lausanne: Bayer, 1997:9. (Poster P1156)
71. Hoogkamp-Korstanje JAA. Activity of BAY 12-8039 against aerobic and anaerobic Gram-positive rods. Eighth European Congress of Clinical Microbiology and Infectious Diseases. May 25-28, 1997. Lausanne: Bayer, 1997:7. (Poster #P1154)
72. Endtz HP, Mouton JW, Den Hollander JG, Van Den Braak N, Verbrugh HA. Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 Gram-positive isolates from patients with endocarditis, and those with other bloodstream infections. Antimicrob Agents Chemother 1997;41:1146-9.
73. Hoogkamp-Korstanje JAA, Dirks-Go SIS, Kabel P, et al. Multicentre in-vitro evaluation of the susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to ciprofloxacin, clarithromycin, co-amoxiclav and sparfloxacin. J Antimicrob Chemother 1997;39:411-4.
74. Crokaert F, Aoun M, Duchateau V, Grenier P, Vandermies A, Klastersky J. In vitro activity of trovafloxacin (CP-99,219), sparfloxacin, ciprofloxacin, and fleroxacin against respiratory pathogens. Eur J Clin Microbiol Infect Dis 1996;15:696-8. (Lett)
75. Cohen MA, Yoder SL, Talbot GH. Sparfloxacin worldwide in vitro literature: isolate data available through 1994. Diagn Microbiol Infect Dis 1996;25:53-64.
76. Cunha BA, Qadri SMH, Ueno Y, Walters EA, Domenico P. Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates. J Antimicrob Chemother 1997;39(Suppl B):29-34.
77. Dembry LM, Farrel PA, Orcutt DR, Gerrity LA, Andriole VT. In-vitro activity of trovafloxacin against sensitive and resistant aerobic bacteria using the standard microdilution broth method and Etest. J Antimicrob Chemother 1997;39(Suppl B):35-42.
78. Klugman KP, Gootz TD. In-vitro and in-vivo activity of trovafloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 1997;39(Suppl B):51-5.
79. Sefton AM, Maskell JP, Rafay AM, Whiley A, Williams JD. The in-vitro activity of trovafloxacin, a new fluoroquinolone, against Gram-positive bacteria. J Antimicrob Chemother 1997;39(Suppl B):57-62.
80. Verbist L, Verhaegen J. In vitro activity of trovafloxacin versus ciprofloxacin against clinical isolates. Eur J Clin Microbiol Infect Dis 1996;15:683-5.
81. Visalli MA, Bajaksouzian S, Jacobs MR, Appelbaum PC. Comparative activity of trovafloxacin, alone and in combination with other agents, against Gram-negative nonfermentative rods. Antimicrob Agents Chemother 1997;41:1475-81.
82. Qadri SMH, Abo-Askar H, Ueno Y. Antibacterial activity of the new quinolone CI-960 (PD 127391) against clinical isolates at a major tertiary care center in Saudi Arabia. Chemotherapy 1992;38:92-8.
83. Citron DM, Appleman MD. Comparative in vitro activities of trovafloxacin (CP-99,219) against 221 aerobic and 217 anaerobic bacteria isolated form patients with intra-abdominal infections. Antimicrob Agents Chemother 1997;41:2312-6.
84. Tanaka M, Hoshino K, Ishida H, Sato K, Hayakawa I, Osada Y. Antimicrobial activity of DV-7751a, a new fluoroquinolone. Antimicrob Agents Chemother 1993;37:2112-8.
85. National Committee for Clinical Laboratory Standards (NCCLS) Methods For Antimicrobial Testing of Anaerobic Bacteria: approved standard M11-A4. Villanova: NCCLS, 1997.
86. Aldridge KE, Ashcraft D, Bowman KA. Comparative in vitro activities of trovafloxacin (CP 99,219) and other antimicrobials against clinically significant anaerobes. Antimicrob Agents Chemother 1997;41:484-7.
87. Wexler HM, Molitoris E, Molitoris D, Finegold SM. In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria. Antimicrob Agents Chemother 1996;40:2232-5.
88. Nord CE. In vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria. Clin Infect Dis 1996;23(Suppl 1):S15-8.
89. Spangler SK, Jacobs MR, Appelbaum PC. Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrob Agents Chemother 1994;38:2471-6.
90. Aldridge KE, Ashcraft DS. Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes. Antimicrob Agents Chemother 1997;41:709-11.
91. Goldstein EJC, Citron DM. Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria. Antimicrob Agents Chemother 1992;36:1158-62.
92. Appelbaum PC. Quinolone activity against anaerobes: microbiological aspects. Drugs 1995;49(Suppl 2):76-80.
93. Hecht DW, Wexler HM. In vitro susceptibility of anaerobes to quinolones in the United States. Clin Infect Dis 1996;23(Suppl 1):S2-8.
94. Kato N, Kato H, Tanaka-Bando K, Watanabe K, Ueno K. Comparison of in vitro activities of DU-6859a and other fluoroquinolones against Japanese isolates of anaerobic bacteria. Clin Infect Dis 1996;23(Suppl 1):S31-5.
95. Nord CE, Edlund C. Susceptibility of anaerobic bacteria to BAY 12-8039, a new methoxyquinolone. Eighth European Congress of Clinical Microbiology and Infectious Diseases. May 25-28, 1997. Lausanne: Bayer, 1997:10. (Poster P1154)
96. Dubois J, St-Pierre C. An in vitro susceptibility study of trovafloxacin against Legionella species. In: Trovafloxacin: A Review of Publications and Congress Presentations. West Sussex: Cambridge Medical Publications, 1997:70-1.
97. Miyashita N, Niki Y, Kishimoto T, Nakajima M, Matsushima T. In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp. Antimicrob Agents Chemother 1997;41:1331-4.
98. Waites KB, Duffy LB, Schmid T, Crabb D, Pate MS, Cassell GH. In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391. Antimicrob Agents Chemother 1991;35:1181-5.
99. Gooding BB, Erwin ME, Barrett MS, Johnson DM, Jones RN. Antimicrobial activities of two investigational fluoroquinolones (CI-960 and E4695) against over 100 Legionella sp isolates. Antimicrob Agents Chemother 1992;36:2049-50.
100. Ullmann U, Shubert S, Krausse R. In vitro activity of gatifloxacin, other fluoroquinolones, doxycyclin and erythromycin against Ureaplasma urealyticum and Mycoplasma hominis. Second European Congress of Chemotherapy and the Seventh Biennial Conference on Anti-Infective Agents and Chemotherapy. June 25-27, 1998. Hamburg: Grunenthal, 1998. (Abst 2)
101. Ridgway GL, Salman H, Robbins MJ, Dencer C, Felmingham D. The in-vitro activity of grepafloxacin against Chlamydia spp, Mycoplasma spp., Ureaplasma urealyticum and Legionella spp. J Antimicrob Chemother 1997;40(Suppl A):31-4.
102. Edelstein PH, Edelstein MAC, Lehr KH, Ren J. In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia. J Antimicrob Chemother 1996;37:117-26.
103. Kaku M, Ishida K, Irifune K, et al. In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae. Antimicrob Agents Chemother 1994;38:738-41.
104. Renaudin H, Bebear CM, Boudjadja A, Bebear C. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone, against mycoplasmas. Thirty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, September 18-20, 1996. (Abst 6009)
105. Roblin PM, Hammerschlag MR. Activity of BAY 12-8039, a new 8-methoxyquinolone, against Chlamydia pneumoniae in vitro. Thirty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, September 18-20, 1996. (Abst F011)
106. Roblin PM, Kutlin A, Hammerschlag MR. In vitro activity of trovafloxacin against Chlamydia pneumoniae. Antimicrob Agents Chemother 1997;41:2033-4.
107. Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219). Antimicrob Agents Chemother 1996;40:1048-9.
108. Vance-Bryan K, Guay DRP, Rotschafer JC. Clinical pharmacokinetics of ciprofloxacin. Clin Pharmacokinet 1990;19:434-61.
109. Bron NJ, Dorr MB, Mant TG, Webb CL, Vassos AB. The tolerance and pharmacokinetics of clinafloxacin. J Antimicrob Chemother 1996;38:1023-9.
110. Stein GE. Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Clin Infect Dis 1996;23(Suppl 1):S19-24.
111. Nakashima M, Uematsu T, Kosuge K, et al. Single-and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob Agents Chemother 1995;39:2635-40.
112. Efthymiopoulos C, Bramer SL, Maroli A. Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males. Clin Pharmacokinet 1997;33(Suppl 1):1-8.
113. Kozawa O, Uematsu T, Matsuno H, Niwa M, Nagashima S, Kanamaru M. Comparative study of pharmacokinetics of two new fluoroquinolones, balofloxacin and grepafloxacin, in elderly subjects. Antimicrob Agents Chemother 1996;40:2824-8.
114. Uematsu T, Nagashima S, Takiguchi Y, Nakashima M. OPC-17116, a new quinolone: phase I study. Thirty-first Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, September 29 to October 2, 1991. (Abst 1481)
115. Koike M, Nii S, Morita S, Akiyama H, Odomi M. OPC-17116, a new quinolone: pharmacokinetics and metabolism in healthy volunteers. Thirty-first Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, September 29 to October 2, 1991. (Abst 1482).
116. Efthymiopoulos C, Bramer SL, Maroli A. Effect of renal impairment on the pharmacokinetics of grepafloxacin. Clin Pharmacokinet 1997;33(Suppl 1):32-8.
117. Efthymiopoulos C, Bramer SL, Maroli A, et al. Grepafloxacin pharmacokinetics in individuals with hepatic dysfunction. Clin Pharmacokinet 1997;33(Suppl 1):25-31.
118. Chien SC, Chow AT, Natarajan J, et al. Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects. Antimicrob Agents Chemother 1997;41:1562-5.
119. Chien SC, Rogge MC, Gisclon LG, et al. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother 1997;41:2256-60.
120. Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997;32:101-19.
121. Goodwin SD, Gallis HA, Chow AT, Wong FA, Flor SC, Bartlett JA. Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 1994;38:799-804.
122. Chien SC, Chow AT, Fowler C, et al. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750 mg and 1 g doses of levofloxacin in healthy volunteers. Thirty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, September 18-20, 1996. (Abst A14).
123. Gisclon LG, Curtin CR, Chien SC, Williams R, Corrado M, Reichl V. The pharmacokinetics of levofloxacin in subjects with renal impairment, and in subjects receiving hemodialysis or continuous ambulatory peritoneal dialysis. Thirty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, September 18-20, 1996. (Abst A13)
124. Levofloxacin Product Monograph. Toronto: Janssen-Ortho, 1998.
125. Stass HH, Dalhoff A, Kubitza D, Ahr G. BAY 12-8039, a new 8-methoxy-quinolone: first pharmacokinetic results in healthy male volunteers. Thirty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, September 18-20, 1996. (Abst F24)
126. Kubitza D, Stass HH, Wingender W, Kuhlmann J. BAY 12-8039, a new 8-methoxy-quinolone: safety, tolerability, and steady state pharmacokinetics in healthy male volunteers. Thirty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, September 18-20, 1996. (Abst F25)
127. Stab H, Dalhoff A, Kubitza D. BAY 12-8039: study on the food effect after oral administration of 200 mg SD to healthy volunteers. Eighth European Congress of Clinical Microbiology and Infectious Diseases. May 25-28, 1997. Lausanne: Bayer, 1997:1. (Poster P386)
128. Montay G, Bruno R, Vergniol JC, et al. Pharmacokinetics of sparfloxacin in humans after single oral administration at doses of 200, 400, 600, and 800 mg. J Clin Pharmacol 1994;34:1071-6.
129. Zix JA, Geerdes-Fenge HF, Rau M, et al. Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. Antimicrob Agents Chemother 1997;41:1668-72.
130. Fillastre JP, Montay G, Bruno R, et al. Pharmacokinetics of sparfloxacin in patients with renal impairment. Antimicrob Agents Chemother 1994;38:733-7.
131. Ritz M, Lode H, Fabbender M, Borner K, Koeppe P, Nord CE. Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora. Antimicrob Agents Chemother 1994;38:455-9.
132. Montay G. Pharmacokinetics of sparfloxacin in healthy volunteers and patients: a review. J Antimicrob Chemother 1996;37(Suppl A):27-39.
133. Johnson R, Geary W, Jensen B. The absolute oral bioavailability of sparfloxacin in healthy male subjects.Thirty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, September 18-20, 1996. (Abst A9)
134. Mugnier P, Taburet AM, Wyld PJ, et al. Pharmacokinetics of sparfloxacin in patients with hepatic failure. Thirty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, October 4-7, 1994. (Abst A45)
135. Vincent J, Venitz J, Teng R, et al. Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin. J Antimicrob Chemother 1997;39(Suppl B):75-80.
136. Teng R, Liston TE, Harris SC. Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. J Antimicrob Chemother 1996;37:955-63.
137. Teng R, Dogolo L, Willavize SA, Friedman HL, Vincent J. Oral bioavailability of trovafloxacin with and without food in health volunteers. J Antimicrob Chemother 1997;39(Suppl B):87-92.
138. Teng R, Harris SC, Nix DE, Schentag JJ, Foulds G, Liston TE. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. J Antimicrob Chemother 1995;36:385-94.
139. Taylor A, Swan S, Marbury T, et al. The effect of varying degrees of renal impairment on the safety, toleration and pharmacokinetics of trovafloxacin. Thirty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September 28 to October 1, 1997. (Abst A-66)
140. Anderson KE, Egger NG, Goeger DE, et al. The safety, toleration and pharmacokinetics of trovafloxacin in patients with hepatic impairment. Thirty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September 28 to October 1, 1997. (Abst A-65)
141. Wilson APR, Gruneberg RN. Ciprofloxacin: 10 years of clinical experience. Somerset: Maxim Medical, 1997:67.
142. Trovafloxacin. Med Lett Drug Ther 1998;40(1022):30-1.
143. Tack KJ, McGuire NM, Eiseman IA. Initial clinical experience with clinafloxacin in the treatment of serious infections. Drugs 1995;49(Suppl 2):488-91.
144. Goehler K, Stahlberg HJ, Guillaume M, Mignot A. Safety, tolerance and food effect after single and multiple oral doses of gatifloxacin, a new fluoroquinolone antibiotic, to healthy caucasian volunteers. Second European Congress of Chemotherapy and the Seventh Biennial Conference on Anti-Infective Agents and Chemotherapy. Hamburg, June 25-27, 1998. (Poster)
145. Efthymiopoulos C, Bramer SL, Maroli A. Effect of food and gastric pH on the bioavailability of grepafloxacin. Clin Pharmacokinet 1997;33(Suppl 1):18-24.
146. Thebault JJ, Montay G, Ebmeier M, et al. Effect of food on the bioavailability of the new quinolone RP-64206. Thirtieth Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, October 21 to 24, 1990. (Abst 1249)
147. Johnson JH, Cooper MA, Andrews JM, Wise R. Pharmacokinetics and inflammatory fluid penetration of sparfloxacin. Antimicrob Agents Chemother 1992;36:2444-6.
148. Wise R, Honeybourne D. A review of the penetration of sparfloxacin into the lower respiratory tract and sinuses. J Antimicrob Chemother 1996;37(Suppl A):57-63.
149. Tanimura H, Uchiyama K, Kashiwagi H. Gallbladder tissue concentrations, biliary excretion and pharmcokinetics of OPC-17116. Drugs 1995;49(Suppl 2):341-3. (Abst)
150. Child J, Andrews JM, Wise R. Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin. Antimicrob Agents Chemother 1995;39:513-5.
151. Takahashi Y, Itoh Y, Doi T, Kuriyama M, Kawada Y. Penetration of OPC-17116, a new quinolone compound, into male genital tracts and its in vitro antibacterial activity. Thirty-first Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, September 29 to October 2, 1991. (Abst 1486)
152. Suzuki K, Horiba M. Penetration of OPC-17116, a new quinolone derivative, into human prostatic fluid. Thirty-first Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, September 29 to October 2, 1991. (Abst 1487)
153. Cook PJ, Andrews JM, Wise R, Honeybourne D, Moudgil H. Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments. J Antimicrob Chemother 1995;35:317-26.
154. Ohnishi H, Tanimura H, Ichimiya G et al. Excretion of levofloxacin into bile and gallbladder tissue. Drugs 1993;45(Suppl 3):260-1. (Abst)
155. Child J, Mortiboy D, Andrews JM, Chow AT, Wise R. Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid. Antimicrob Agents Chemother 1995;39:2749-51.
156. Shimada J, Nogita T, Ishibashi Y. Clinical pharmacokinetics of sparfloxacin. Clin Pharmacokinet 1993;25:358-69.
157. Cutler NR, Vincent J, Jhee SS, et al. Penetration of tovafloxacin into cerebrospinal fluid in humans following intravenous infusion of alatrofloxacin. Antimicrob Agents Chemother 1997;41:1298-300.
158. Wise R, Mortiboy D, Child J, Andrews JM. Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219). Antimicrob Agents Chemother 1996;4047-9.
159. Childs S, Gleason D, Immergut M, et al. Penetration of trovafloxacin into prostatic tissue following multiple dosing in man. Thirty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September 28 to October 1, 1997. (Abst A-67)
160. Andrews JM, Honeybourne D, Brenwald NP, et al. Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 1997;39:797-802.
161. Lode H. Clinafloxacin vs ceftazidime study demographic summary. Second European Congress of Chemotherapy and the Seventh Biennial Conference on Anti-Infective Agents and Chemotherapy. Hamburg, June 25-27, 1998.
162. Chodosh S, Lakshminarayan S, Swarz H, Breisch S. Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily. Antimicrob Agents Chemother 1998;42:114-20.
163. Langan CE, Cranfield R, Breisch S, Pettit R. Randomized, double-blind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1997;40(Suppl A):63-72.
164. Kobayashi H. A multicenter, double-blind comparative study of grepafloxacin (GPFX) versus ofloxacin in the treatment of chronic tract respiratory infection.Thirty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, September 18-20, 1996. (Abst LM15)
165. O'Doherty B, Dutchman DA, Pettit R, Maroli A. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother 1997;40(Suppl A):73-81.
166. Patel T, Desai R, Duff J, Johnson ME, Briesch SA, Maroli AN. Comparison of grepafloxacin with clarithromycin in the treatment of community-acquired pneumonia. Thirty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September 28 to October 1, 1997. (Abst LM-69)
167. Kobayashi H. A multicenter, double-blind comparative study of
168. DeAbate CA, Russell M, McElvaine P, et al. Safety and efficacy of oral levofloxacin versus cefuroxime axetil in acute bacterial exacerbations of chronic bronchitis. Respir Care 1997;42:206-13.
169. Shah PM, and members of the International Study Group. Levofloxacin vs cefuroxime axetil in the treatment of acute exacerbations of chronic bronchitis. Thirty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September 28 to October 1, 1997. (Abst LM-38)
170. Habib MP, Gentry LO, Rodriguez-Gomez G, et al. Multicenter randomized study comparing efficacy and safety of oral levofloxacin and cefaclor in treatment of acute bacterial exacerbations of chronic bronchitis. Infect Dis Clin Pract 1998;7:101-9.
171. File JR TM, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997;41:1965-72.
172. Carbon C, and members of the International Study Group. Comparative study of levofloxacin and Co-amoxiclav in the treatment of community-acquired pneumonia in adults. Thirty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September 28 to October 1, 1997. (Abst LM70)
173. Shishido H, Furukawa K, Nagai H, Kawakami K, Kono H. Oral levofloxacin 600mg and 300mg daily doses in difflcult-to-treat respiratory infections. Drugs 1995;49(Suppl 2):433-5. (Abst)
174. Nakamori Y, Miyashita Y, Nakatani I, Nakata K. Levofloxacin: penetration into sputum and once-daily treatment of respiratory tract infections. Drugs 1995;49(Suppl 2):418-9. (Abst)
175. Kawai T. Clinical evaluation of levofloxacin 200mg 3 times daily in the treatment of bacterial lower respiratory tract infections. Drugs 1995;49(Suppl 2):416-7. (Abst)
176. Sato A, Ogawa H, Iwata M, et al. Clinical efficacy of levofloxacin in elderly patients with respiratory tract infections. Drugs 1995;49(Suppl 2):428-9. (Abst)
177. DeAbate CA, for the SPAR Multicentre ABECB Study Group. Treatment of acute bacterial exacerbations of chronic bronchitis with sparfloxacin and ofloxacin. Thirty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, September 18-20, 1996. (Abst LM9)
178. Allegra L, Konietzko N, Leophonte P, et al. Comparative safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a double-blind, randomised, parallel, multicentre study. J Antimicrob Chemother 1996;37(Suppl A):93-104.
179. Taytard A, Gil Aguado A, Vogel F. Short (5 days) course of sparfloxacin in the treatment of acute exacerbation of chronic bronchitis. First European Congress of Chemotherapy, 1996. May 14-17, 1996. (Abst W169)
180. Lode H, Garau J, Grassi C, et al. Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin. Eur Respir J 1995;8:1999-2007.
181. Bensch G, for the SPAR Multicentre CAP Study Group. Treatment of community-acquired pneumonia with sparfloxacin and erythromycin. Thirty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, September 18-20, 1996. (Abst LM12)
182. Donowitz Gfor the SPAR Multicentre CAP Study Group. Treatment of community acquired pneumonia with sparfloxacin and cefaclor. Thirty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, September 18-20, 1996. (Abst LM10)
183. Ortqvist A, Valtonen M, Cars O, Wahl M, Saikku P, Jean C. Oral empiric treatment of community-acquired pneumonia. Chest 1996;110:1499-506.
184. Portier H, May TH, Proust A. Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia. J Antimicrob Chemother 1996;37(Suppl A):83-91.
185. Aubier M, Verster R, Regamey C, Geslin P, Vercken JB. Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Clin Infect Dis 1998;26:1312-20.
186. Niederman, M, Traub S, Ellison WT, Hopkins DW. A double-blind, randomized, multicenter, global study in hospitalized community-acquired pneumonia comparing trovafloxacin with ceftriaxone with or without erythromycin. Second European Congress of Chemotherapy. Hamburg, June 25-27, 1998. (Poster)
187. Sullivan J, Gezon J, Hopkins DW. A double blind, randomized, multicenter study in ambulatory community acquired pneumonia comparing trovafloxacin with clarithromycin. Thirty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September 28 to October 1, 1997. (Abst LM-73)
188. Mandell L, Hopkins DW, Hopkins S. Efficacy of trovafloxacin in patients with community acquired pneumonia due to penicillin susceptible and resistant S pneumoniae. Thirty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September 28 to October 1, 1997. (Abst LM-71)
189. Graham DR, Klein T, Torres A, Niedermann M. A double blind, randomized, multicenter study of nosocomial pneumonia comparing trovafloxacin with ciprofloxacin with or without clindamycin/metronidazole. Thirty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September 28 to October 1, 1997. (Abst LM-74)
190. Suzuki K, Katoh S, Horiba M, Ishikawa K, Hoshinaga K, Naide Y. Gatifloxacin, a newer quinolone derivative in the treatment of chronic bacterial prostatitis. Second European Congress of Chemotherapy and the Seventh Biennial Conference on Anti-Infective Agents and Chemotherapy. Hamburg, June 25-27, 1998. (Poster)
191. Hook EW III, McCormack WM, Martin D, et al. Comparison of Single-dose oral grepafloxacin with cefixime for treatment of uncomplicated gonorrhea in men. Antimicrob Agents Chemother 1997;41:1843-5.
192. Matsuda S. A multicenter, double-blind comparative study of grepafloxacin versus ofloxacin in the treatment of obstetric and gynecological infection. Thirty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, September 18-20, 1996. (Abst LM16)
193. Mroczkowski TF, Bean KA, Martin DH. A dose ranging study of a new quinolone, OPC-17116, for the treatment of Chlamydia trachomatis (Ct) infection in women. Sex Transm Dis 1994;21(Suppl 2):S106-7. (Lett)
194. Mroczkowski TF, Martin DH, Bean KA, et al. OPC-17116 in the treatment of gonococcal and chlamydial cervicitis. J Eur Acad Dermetal Venercel 1995;(Suppl 1):577. (Abst 30)
195. Richard GA, Klimberg IN, Fowler C, Callery-D'Amico S. A combined analysis of two studies comparing levofloxacin with two other fluoroquinolones for the treatment of acute pyelonephritis. Thirty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, September 18-20, 1996. (Abst LM3)
196. Klimberg IV, Cox CE II, Fowler CL, King W, Kim SS, Callery-D'Amico S. A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection. Urology 1998;51:610-5.
197. Suzuki K, Horiba M, Tanaka T, Naide Y, Yonetsu M. Levofloxacin in the treatment of chronic prostatitis. Drugs 1993;45(Suppl 3):368-9. (Abst)
198. Moi H, Morel P, Gianotti B, Barlow D, Phillips I, Jean C. Comparative efficacy and safety of single oral doses of sparfloxacin versus ciprofloxacin in the treatment of acute gonococcal urethritis in men. J Antimicrob Chemother 1996;37(Suppl A):115-22.
199. Phillips I, Dimian C, Barlow D, et al. A comparative study of two different regimens of sparfloxacin versus doxycycline in the treatment of non-gonococcal urethritis in men. J Antimicrob Chemother 1996;3 7(Suppl A):123-34.
200. Naber KG, Di Silverio F, Geddes A, Guibert J. Comparative efficacy of sparfloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection. J Antimicrob Chemother 1996;37(Suppl A):135-44.
201. Iravani A, for the SPAR Multicentre UUTI Study Group. Treatment of community-acquired acute uncomplicated urinary tract infections with sparfloxacin and ciprofloxacin.Thirty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, September 18-20, 1996. (Abst LM6)
202. Henry D, for the SPAR Multicentre UUTI Study Group. Treatment of community-acquired acute uncomplicated urinary tract infections with sparfloxacin and ofloxacin.Thirty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, September 18-20, 1996. (Abst LM7)
203. Kawada Y, two other authors, et al. Sparfloxacin in the treatment of genitourinary tract infections. Drugs 1993;45(Suppl 3):339. (Abst)
204. Matsuda S, two other authors, et al. Clinical experience with sparfloxacin in the treatment of gynaecological infection. Drugs 1993;45(Suppl 3):384. (Abst)
205. Hook III EW, Pinson GB, Blalock CJ, Johnson RB. Dose-ranging study of CP-99,219 (trovafloxacin) for treatment of uncomplicated gonorrhea. Antimicrob Agents Chemother 1996;40:1720-1.
206. Jones RB, Schwebke J, Thorpe Jr EM, Dalu ZA, Leone P, Johnson RB. Randomized trial of trovafloxacin and ofloxacin for single-dose therapy of gonorrhea. Am J Med 1998;104:28-32.
207. Arata J, et al. A multicenter, double-blind comparative study of grepafloxacin versus ofloxacin in the treatment of skin and skin structure infections. Thirty-sixth interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, September 18-20, 1996. (Abst LM17)
208. Nicodemo AC, Robledo JA, Jasovich A, Neto W. A multicenter, double-blind, randomized study comparing the efficacy and safety of oral levofloxacin versus ciprofloxacin in the treatment of uncomplicated skin and skin structure infections. Int J Clin Pract 1998;52:69-74.
209. Nichols RL, Smith JW, Gentry LO, et al. Multicenter, randomized study comparing levofloxacin and ciprofloxacin for uncomplicated skin and skin structure infections. South Med J 1997;90:1192-200.
210. Lipsky BA, for the SPAR Multicentre SSSI Study Group. Treatment of community-acquired complicated skin and skin structure infections with sparfloxacin. Thirty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, September 18-20, 1996. (Abst LM11)
211. Takahashi H, and the Japanese Collabotative Study Group of Sparfloxacin in dermatology. Sparfloxacin in the treatment of skin and soft tissue infections. Drugs 1993;45(Suppl 3):386. (Abst)
212. Watanabe T, Akieda Y, Suzuki T, Itokawa K, Yamaji E, Nakayama I. Clinical trials of a new quinolone, sparfloxacin, in skin and skin structure infections. Drugs 1993;45(Suppl 3):388-9. (Abst)
213. Wilson SE. Intra-abdominal infection trial: clinafloxacin vs. imipenem. Second European Congress of Chemotherapy and the Seventh Biennial Conference on Anti-Infective Agents and Chemotherapy. Hamburg, June 25-27, 1998.
214. Bartlett JG, Breiman RF, Mandell LA, File TM Jr. Community-acquired penumoniae in adults: guidelines for management. Clin Infect Dis 1998;26:811-38.
215. Wise R, Brenwald N, Gill M, Fraise A. Streptococcus pneumoniae resistance to fluoroquinolones. Lancet 1996;348:1660.
216. Goldstein EJC. Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety. Clin Infect Dis 1996;23(Suppl 1):S25-30.
217. Stahlmann R, Schwabe R. Safety profile of grepafloxacin compared with other fluoroquinolones. J Antimicrob Chemother 1997;40(Suppl A):83-92.
218. Grepafloxacin - a new fluoroquinolone. Med Lett Drug Ther 1998;40(1019):17-8.
219. Sullivan JT, Kubitza D, Schuhly U, Wingender W. Safety of the new quinolone BAY 12-8039 in 130 healthy volunteers. Twentieth International Congress of Chemotherapy. June 29 to July 3, 1997. Sydney: Bayer AG, 1997:16. (Abst)
220. Sullivan JT, Woodruff M, Lettieri J, Agarwal V, Krol G, Heller AH. Pharmacokinetics and tolerability of the new methoxyquinolone BAY 12-8039: 10 days' treatment at 400 mg daily. Eighth European Congress of Clinical Microbiology and Infectious Diseases. May 25-28, 1998. Lausanne: Bayer, 1997. (Poster P389).
221. Rubinstein E. Safety profile of sparfloxacin in the treatment of respiratory tract infections. J Antimicrob Chemother 1996;37(Suppl A):145-60.
222. Jaillon P, Morganroth J, Brumpt I, Talbot G. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. J Antimicrob Chemother 1996;37(Suppl A):161-7.
223. Haria M, Lamb HM. Trovafloxacin. Drugs 1997;54:435-45.
224. Ferguson J, McEwen J, Patterson BE, Purkins L, Colman PJ, Willavize SA. An open, observer-blinded, placebo-controlled, randomized, parallel-group study to investigate the phototoxic potential of trovafloxacin, ciprofloxacin and lomefloxacin. In: Trovafloxacin: A Review of Publications and Congress Presentations. West Sussex: Cambridge Medical Publications, 1997:148-9. (Abst)
225. Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B. Torsades de pointe probably related to sparfloxacin. Eur J Clin Microbiol Infect Dis 1996;15:350-1. (Lett)
226. Lietman PS. Fluoroquinolone toxicities: An update. Drugs 1995;49(Suppl 2):159-63.
227. Ferguson J, Dawe R. Phototoxicity in quinolones: comparison of ciprofloxacin and grepafloxacin. J Antimicrob Chemother 1997;40(Suppl A):93-8.
228. Ball P, Tillotson G. Tolerability of fluoroquinolone antibiotics. Drug Saf 1995;13:343-58.
229. Stahlmann R, Forster C, Van Sickle D. Quinolones in children. Are concerns over arthropathy justified. Drug Saf 1993;9:397-403.
230. Schaad UB. Role of the new quinolones in pediatric practice. Pediatr Infect Dis J 1992;11:1043-6.
231. Kubin R. Safety and efficacy of ciprofloxacin in paediatric patients - review. Infection 1993;21:413-21.
232. Martell M, de Ben S, Weinberger M, Beltrami G. Growth and development in preterm infants receiving fluoroquinolones. J Perinat Med 1996;24:287-91.
233. Shiba K, Sakai O, Shimada J, Okazaki O, Aoki H, Hakusui H. Effects of antacids, ferrous sulfate, and ranitidine on absorption of DR-3355 in humans. Antimicrob Agents Chemother 1992;36:2270-4.
234. Shiba K, Sakamoto M, Nakazawa Y, Sakai O. Effects of antacid on absorption and excretion of new quinolones. Drugs 1995;49(Suppl 2):360-1. (Abst)
235. Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J. Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. J Antimicrob Chemother 1997;39(Suppl B):93-7.
236. Stab HH, Boettcher M, Horstmann R. Study to evaluate the interaction between BAY 12-8039 and antacids. Twentieth International Congress of Chemotherapy. June 29 to July 3, 1997. Sydney: Bayer AG, 1997:13. (Abst)
237. Mignot A, Douin MJ, Millerioux L, et al. Effect of aluminum hydroxide antacid on the pharmacokinetics of the new quinolone RP-64206. Thirtieth Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, October 21 to 24, 1990. (Abst 1250)
238. Kanemitsu K, Hori S, Yanagawa A, Shimada J. Effect of ferrous sulfate on the absorption of sparfloxacin in healthy volunteers and rats. Drugs 1995;49(Suppl 2)352-6. (Abst)
239. Shiba K, Sakamoto M, Saito A, et al. Effect of ferrous sulfate, tea and milk on absorption of AM-1155, a 6-fluoro-8-methoxy quinolone in humans. Thirty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 17-20, 1995. (Abst A43)
240. Lee LJ, Hafkin B, Lee ID, Hoh J, Dix R. Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects. Antimicrob Agents Chemother 1997;41:2196-200.
241. Matuschka PR, Vissing RS. Clinafloxacin-theophylline drug interaction. Ann Pharmacother 1995;29:378-80.
242. Niki Y, Hashiguchi K, Okimoto N, Soejima R. Quinolone antimicrobial agents and theophylline. Chest 1992;101:881. (Lett)
243. Efthymiopoulos C, Bramer SL, Maroli A, Blum B. Theophylline and warfarin interaction studies with grepafloxacin. Clin Pharmacokinet 1997;33(Suppl 1):39-46.
244. Stab HH, Kubitza D, Schwietert H, Wemer R. BAY 12-8039 does not interact with theophylline. Twentieth International Congress of Chemotherapy. June 29 to July 3, 1997. Sydney: Bayer AG, 1997:15. (Abst)
245. Gisclon LG, Curtin CR, Fowler CL, Williams RR, Hafkin B, Natarajan J. Absence of a pharmacokinetic interaction between intravenous theophylline and orally administered levofloxacin. J Clin Pharmacol 1997;37:744-50.
246. Takagi K, Yamaki K, Nadai M, Kuzuya T, Hasegawa T. Effect of a new quinolone, sparfloxacin, on the pharmacokinetics of theophylline in asthmatic patients. Antimicrob Agents Chemother 1991;35:1137-41.
247. Dickens GR, Wermeling D, Vincent J. Phase I pilot study of the effects of trovafloxacin (CP-99,219) on the pharmacokinetics of theophylline in healthy men. J Clin Pharmacol 1997;37:248-352.
248. Vincent J, Teng R, Dogolo LC, Willavize SA, Friedman HL. Effect of trovafloxacin, a new fluoroquinolone antibiotic, on the steady-state pharmacokinetics of theophylline in healthy volunteers. J Antimicrob Chemother 1997;39(Suppl B):81-6.
249. Springuel P. Drugs causing prolongation of QT interval and torsades de pointes. Can Med Assoc J 1998;158:103-4.
250. Liao S, Palmer M, Fowler CA, Nayak RK. Absence of an effect of levofloxacin on warfarin pharmacokinetics and anticoagulation in male volunteers. Thirty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 17-20, 1995. (Abst A42)
251. Teng R, Apseloff G, Vincent J, Pelletier SM, Willavize SA, Friedman HL. Effect of trovafloxacin (CP-99,219) on the pharmacokinetics and pharmacodynamics of warfarin in healthy male subjects. In: Trovafloxacin: A Review of Publications and Congress Presentations. West Sussex: Cambridge Medical Publications, 1997:140-1. (Poster)
252. The choice of antibacterial drugs. Med Letter Drug Ther 1998;40:33-42.
253. Balfour JA, Faulds D. Oral ciprofloxacin: a pharmacoeconomic evaluation of its use in the treatment of serious infections. Pharmacoeconomics 1993;3:398-421.
254. Paladino JA, Sperry HE, Backes JM, et al. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. Am J Med 1991;91:462-70.
255. Fliegelman RM, Mattingly PM, Dempsey CL, Sokalsi SJ. Economic impact of oral ciprofloxacin following standard intravenous therapy. Diagn Microb Infect Dis 1990;13:187-9.
256. Paladino JA. Pharmacoeconomic comparison of sequential IV/Oral ciprofloxacin versus ceftazidime in the treatment of nosocomial pneumonia. Can J Hosp Pharm 1995;48:276-83.
257. Canadian Coordinating Office for Health Technology Assessment. Clinical and Economic Considerations in the Use of Fluoroquinolones. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 1997.